These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30370830)

  • 1. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
    Wynne J; Muwawu R; Mubiru MC; Kamira B; Kemigisha D; Nakyanzi T; Kabwigu S; Nakabiito C; Kiweewa Matovu F
    HIV Clin Trials; 2018 Oct; 19(5):165-171. PubMed ID: 30370830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
    Mensch BS; Brown ER; Liu K; Marrazzo J; Chirenje ZM; Gomez K; Piper J; Patterson K; van der Straten A
    AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
    Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
    AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe.
    Gappoo S; Montgomery ET; Gerdts C; Naidoo S; Chidanyika A; Nkala B; Ramjee G;
    Contemp Clin Trials; 2009 Sep; 30(5):411-8. PubMed ID: 19481617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa.
    Abbai NS; Nyirenda M; Naidoo S; Ramjee G
    AIDS Behav; 2018 Jul; 22(7):2172-2180. PubMed ID: 28956191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.
    Malahleha M; Ahmed K; Deese J; Nanda K; van Damme L; De Baetselier I; Burnett RJ
    J Med Case Rep; 2015 Sep; 9():207. PubMed ID: 26411737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017).
    Liu AY; Norwood A; Gundacker H; Carballo-Diéguez A; Johnson S; Patterson K; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Mayer KH; Zorrilla C; Buchbinder S; Piper JM; Lama JR; Cranston RD
    J Acquir Immune Defic Syndr; 2019 Aug; 81(5):516-520. PubMed ID: 31299013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invited commentary: every good randomization deserves observation.
    Westreich D; Edwards JK
    Am J Epidemiol; 2015 Nov; 182(10):857-60. PubMed ID: 26487342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of HIV seroconverters in microbicide trials - rationale, study design, and challenges in MTN-015.
    Riddler SA; Husnik M; Gorbach PM; Levy L; Parikh U; Livant E; Pather A; Makanani B; Muhlanga F; Kasaro M; Martinson F; Elharrar V; Balkus JE;
    HIV Clin Trials; 2016 Sep; 17(5):204-11. PubMed ID: 27465646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disclosure of pharmacokinetic drug results to understand nonadherence.
    van der Straten A; Montgomery ET; Musara P; Etima J; Naidoo S; Laborde N; Hartmann M; Levy L; Bennie T; Cheng H; Piper J; Grossman CI; Marrazzo J; Mensch B;
    AIDS; 2015 Oct; 29(16):2161-71. PubMed ID: 26544581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.
    Dai JY; Hendrix CW; Richardson BA; Kelly C; Marzinke M; Chirenje ZM; Marrazzo JM; Brown ER
    J Infect Dis; 2016 Feb; 213(3):335-42. PubMed ID: 26123563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
    Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA
    Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.